A Multigene Urine Test for the Detection and Stratification of Bladder Cancer in Patients Presenting with Hematuria

PurposeWe investigated whether the RNA assay uRNA® and its derivative Cxbladder® have greater sensitivity for the detection of bladder cancer than cytology, NMP22™ BladderChek™ and NMP22™ ELISA, and whether they are useful in risk stratification.Materials and MethodsA total of 485 patients presenting with gross hematuria but without a history of urothelial cancer were recruited prospectively from 11 urology clinics in Australasia. Voided urine samples were obtained before cystoscopy. The sensitivity and specificity of the RNA tests were compared to cytology and the NMP22 assays using cystoscopy as the reference. The ability of Cxbladder to distinguish between low grade, stage Ta urothelial carcinoma and more advanced urothelial carcinoma was also determined.ResultsuRNA detected 41 of 66 urothelial carcinoma cases (62.1% sensitivity, 95% CI 49.3–73.8) compared with NMP22 ELISA (50.0%, 95% CI 37.4–62.6), BladderChek (37.9%, 95% CI 26.2–50.7) and cytology (56.1%, 95% CI 43.8–68.3). Cxbladder, which was developed on the study data, detected 82%, including 97% of the high grade tumors and 100% of tumors stage 1 or greater. The cutoffs for uRNA and Cxbladder were prespecified to give a specificity of 85%. The specificity of cytology was 94.5% (95% CI 91.9–96.5), NMP22 ELISA 88.0%, (95% CI 84.6–91.0) and BladderChek 96.4% (95% CI 94.2–98.0). Cxbladder distinguished between low grade Ta tumors and other detected urothelial carcinoma with a sensitivity of 91% and a specificity of 90%.ConclusionsuRNA and Cxbladder showed improved sensitivity for the detection of urothelial carcinoma compared to the NMP22 assays. Stratification with Cxbladder provides a potential method to prioritize patients for the management of waiting lists.